KaydedilenlerDerginizi ekleyin

Dergiler / Annals of Medical Sciences / 2001 / Cilt: 10 - Sayı: 2

Serum ICAM-1 levels in kidney transplantation

Yıldırım BAYAZIT
Ramazan GÜNEŞAÇAR
Eren ERKEN
Kaan KOCAOLUK
Uğur ERKEN
Sayfa
71–74
Yayın Tarihi
2022-10-10
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We can conclude that serum ICAM-1 level measurement is not a specific parameter for detection of chronic renal graft rejection.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Purpose: Intercellular adhesion molecule-1 (ICAM-1) is a member of immunoglobulin superfamily and acts as a ligand for the LFA-1 which is a leukocyte integrin.
📊
Temel Bulgular & Veri:ICAM-1 has a role in the pathogenesis of various inflammatory processes and allograft rejection in kidney and heart transplantation.
💡
Sonuç & Katkı:We can conclude that serum ICAM-1 level measurement is not a specific parameter for detection of chronic renal graft rejection.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Purpose: Intercellular adhesion molecule-1 (ICAM-1) is a member of immunoglobulin superfamily and acts as a ligand for the LFA-1 which is a leukocyte integrin. ICAM-1 has a role in the pathogenesis of various inflammatory processes and allograft rejection in kidney and heart transplantation. The aim of this study is to compare the serum ICAM-1 levels of kidney recipients with chronic rejection, recipients with functioning renal allografts and healthy controls. Methods: In this prospective study, serum ICAM-1 values of the 31 kidney transplantation patients (15 with normally functioning grafts and 16 with chronically rejected grafts) and 21 healthy controls were determined with ELISA method. Triple drug immunosuppressive regimen (cyclosporine + azathioprine + methylprednisolone) was given to the patients with kidney grafts. Results: The mean serum ICAM-1 level of the patients with chronic rejection (379.5±244.3 ng/ml) was higher than that of patients with functioning grafts (268.8±88 ng/ml). Although this difference was found to be statistically insignificant (p=0.057), it was close to the significancy limit. There was no statistically significant difference between the serum ICAM-1 levels of the patients either with chronic rejection or functioning grafts and those of healthy controls (307.3±63.6 ng/ml) (p=0.96 and p=0.07 respectively). Conclusion: Our findings suggest that, normal serum levels of ICAM-1 in patients with functioning grafts may be a result of proper immunosuppression. Elevated serum ICAM-1 levels in patients with chronic graft rejection indicate an activation in the immune system. We can conclude that serum ICAM-1 level measurement is not a specific parameter for detection of chronic renal graft rejection.

🔖

Bu Makaleye Atıf Yap

BAYAZIT, Y., GÜNEŞAÇAR, R., ERKEN, E., KOCAOLUK, K., ERKEN, U. (2022). Serum ICAM-1 levels in kidney transplantation. Annals of Medical Sciences, Cilt: 10 - Sayı: 2, 71–74. https://ajindex.com/articles/447475

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Carlos T.M., Harlan J.M.: Leukocyte-endotheial adhesion molecules. Blood, 1994
  2. Stockenhuber F., Kramer G., Schenn G., Pec M., Keil M., Gnant M., Steininger R., Balcke P., Mühlbacher F.: Circulating ICAM-1: Novel parameter of renal graft rejection. Transplant Proc, 1993
  3. Chan R.D., Greenstein S.M., Tellis V., Corey H.E.: Renal tubular cells express ICAM-1 during allograft rejection. Transplant Proc, 1993
  4. Cosimi A.B., Conti D., Delmonico F.L., Preffer F.I., Wee S.L., Rothlein R., Faanes R., Colvin R.B.: In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol, 1990
  5. Kanagawa K., Seki T., Nishigaki F., Takeuchi I., Tanda K., Nonomura K., Chikaraishi T., Togashi M., Hirano T., Koyanagi T.: Measurement of soluble ICAM-1 after renal transplantation. Transplant Proc, 1994
  6. Suranyi M.G., Bishop G.A., Clayberger C., KrenskyA.M., Leenaerts P., Aversa G., Hall B.M.: Lymhocyte adhesion molecules in T cell-mediated lysis of human kidney cells. Kidney Int, 1991
  7. Lebranchu Y., Kapahi P., Najjar A.A., Sharobeem R., Valentin J.F., Nivet H., Bagros Ph., Haskard D.: Soluble E-selectin, ICAM-1, and VCAM-1 levels in renal allograft recipients. Transplant Proc, 1994
  8. Dallman M.J., Morris P.J.: Immunology of rejection. In: P.J. Morris, editor. Kidney Transplantation Principles and Practice. 4th ed., Philadelphia, W. B. Saunders Company, 1994
  9. pp:8-25. 9.Elovaara I., Lällä M., Spåre E., Lehtimäki T., Dastidar P.: Methylprednisolone reduces adhesion molecules in blood and cerebrospinal fluid in patients with MS. Neurology, 1998
  10. Yoshida N., Yoshikawa T., Nakamura Y., Takenaka S., Sakamoto K., Manabe H., Nakagawa S., Kondo M.: Methylprednisolone inhibits neutrophil-endothelial cell interactions induced by interleukin-1β under flow conditions. Life Sciences, 1997
  11. Youssef P.P., Triantafillou S., Parker A., Coleman M., Roberts-Thomson P.J., Ahern M.J., Smith M.D.: Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Arthritis Rheum, 1996
  12. Shiota Y., Wilson J.G., Marukawa M., Ono T., Kaji M.: Soluble intercellular adhesion molecule 1 (ICAM-1) antigen in sera of bronchial asthmatics. Chest, 1996
  13. Franciotta D., Piccolo G., Zardini E., Bergamaschi R., Cosi V.: Soluble CD8 and ICAM-1 in serum and CSF of